Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
10.67
-0.07 (-0.65%)
At close: Mar 6, 2026, 4:00 PM EST
10.46
-0.21 (-1.97%)
After-hours: Mar 6, 2026, 7:39 PM EST
Company Description
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.
It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 371 |
| CEO | Steven Basta |
Contact Details
Address: 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 United States | |
| Phone | 877 742 8466 |
| Website | phathompharma.com |
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| Employer ID | 82-4151574 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven L. Basta M.B.A. | Chief Executive Officer, President and Director |
| David A. Socks | Co-Founder |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder |
| Sanjeev Narula | Chief Financial and Business Officer |
| Jonathan Bentley | Senior Vice President and Head of Sales, Operations and Training |
| Robert Breedlove | Vice President of Finance and Principal Accounting Officer |
| Eric Sciorilli | Director of Business Development and Investor Relations |
| Bill Aprea J.D. | Senior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer |
| Anne Marie Cook Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Nancy R. Phelan | Senior Vice President of Marketing and Analytics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Jan 27, 2026 | SCHEDULE 13G/A | Filing |
| Jan 8, 2026 | 8-K | Current Report |
| Jan 8, 2026 | 424B5 | Filing |
| Jan 7, 2026 | 424B5 | Filing |
| Jan 7, 2026 | 8-K | Current Report |
| Jan 7, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Nov 4, 2025 | SCHEDULE 13D/A | Filing |
| Nov 4, 2025 | 8-K | Current Report |